Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 4, 2012, Pages 655-662

  Leung, Elaine Y L ^a   Scott, Hazel R ^b   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WISHAW GENERAL HOSPITAL   (United Kingdom)

Author keywords

Clinical utility; Glasgow prognostic score; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

AGED; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOLLOW UP; GLASGOW PROGNOSTIC SCORE; HUMAN; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL;

EID: 84858763316     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318244ffe1     Document Type: Article

References (30)

1. Cancer Research UK (CRUK). Cancer statistics: lung cancer; 2008. Available at: http://info.cancerresearchuk.org/cancerstats/types/lung/.
2. Scottish Executive Health Department. Cancer scenarios: an aid to planning cancer services in Scotland in the next decade; 2001. Available at: http://www.sehd.scot.nhs.uk/publications/csatp/csatp-00.htm.
3. Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002;87:264-267.
4. Gioulbasanis I, Baracos VE, Giannousi Z, et al. Baseline nutritional evaluation in metastatic lung cancer patients: mini nutritional assessment versus weight loss history. Ann Oncol 2011;22:835-841.
5. MacDonald N. Cancer cachexia and targeting chronic inflammation: a unified approach to cancer treatment and palliative/supportive care. J Support Oncol 2007;5:157-162. (Pubitemid 46929225)
6. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-226.
7. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mgps) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 2011;104:726-734.
8. Wilop S, Crysandt M, Bendel M, et al. Correlation of c-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 2008;31:665-670.
9. Koch A, Fohlin H, Sörenson S. Prognostic significance of c-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 2009;4:326.
10. Gagnon B, Abrahamowicz M, Xiao Y, et al. Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 2010;102:1113-1122.
11. Arrieta O, Ortega M, Rosa M, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 2010;10:50.
12. Forrest LM, McMillan DC, McArdle CS, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 2004;90:1704-1706. (Pubitemid 38725637)
13. Forrest LM, McMillan DC, McArdle CS, et al. A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005;92:1834-1836. (Pubitemid 40826128)
14. Brown DJF, Milroy R, Preston T, et al. The relationship between an inflammation-based prognostic score (Glasgow Prognostic Score) and changes in serum biochemical variables in patients with advanced lung and gastrointestinal cancer. J Clin Pathol 2007;60:705-708. (Pubitemid 46975230)
15. Mountain CF, Greenberg SD, Fraire AE. Tumor stage in non-small cell carcinoma of the lung. Chest 1991;99:1258-1260.
16. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030. (Pubitemid 37239206)
17. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007;22:881-886. (Pubitemid 46952036)
18. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008;67:257-262.
19. Kasymjanova G, Macdonald N, Agulnik JS, et al. The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 2010;17:52-58.
20. Crumley AB, Stuart RC, McKernan M, et al. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg 2010;14:781-787.
21. Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum c-reactive protein and TNM classification: the TNM-C score. J Urol 2009;181:1004-1012.
22. Gakis G, Todenhoefer T, Renninger M, et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011;108:1800-1805.
23. Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 2011;47:2633-2641.
24. Du Clos TW, Mold C. C-Reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 2004;30:261-277. (Pubitemid 39546229)
25. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum c-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol 2000;23:263.
26. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867. (Pubitemid 36019639)
27. Abramovitch R, Marikovsky M, Meir G, et al. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 1999;79:1392-1398. (Pubitemid 29116795)
28. Canna K, Hilmy M, McMillan DC, et al. The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis 2008;10:663-667.
29. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-163.
30. Clarke SJ, Chua W, Moore M, et al. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther 2011;90:475-478.